Farther Finance Advisors’s Heron Therapeutics HRTX Stock Holding History

Farther Finance Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.37K	Buy	10,753 +10,578	+6,045%	+$4.01K	﹤0.01%	5193
2026 Q2	$75	Buy	175 +22	+14%	+$18	﹤0.01%	5820
2026 Q1	$123	Buy	153 +101	+194%	+$117	﹤0.01%	5490
2025 Q4	$68	Buy	+52	New	+$64	﹤0.01%	5330
2024 Q3	–	Sell	-555	Closed	-$1.93K	–	4057
2024 Q2	$1.93K	Buy	+555	New	+$1.71K	﹤0.01%	2809
2023 Q3	–	Sell	-100	Closed	-$116	–	2648
2023 Q2	$116	Buy	+100	New	+$178	﹤0.01%	2419

Other funds holding HRTX

Apeiron RIA Dallas, Texas $440M AUM 15.34% 1-Year Est. Return

DIM

DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's HRTX Position: Q3 2026 in Review

Farther Finance Advisors increased its Heron Therapeutics (HRTX) stake by 6,045% in Q3 2026, buying an estimated $4.01K and bringing the position to 10,753 shares worth $3.37K. The position accounts for ﹤0.01% of the portfolio, ranked #5193.

Farther Finance Advisors first reported a position in HRTX in Q2 2023 and has held it in 6 quarters since. 5 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

Farther Finance Advisors held 10,753 shares of Heron Therapeutics worth $3.37K as of Q3 2026.
Farther Finance Advisors bought 10,578 Heron Therapeutics shares in Q3 2026, an estimated $4.01K.
Heron Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5193 holding.
Farther Finance Advisors first reported a position in Heron Therapeutics in Q2 2023 and has held it in 6 quarters since.
5 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.